JP7638960B2 - Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン - Google Patents

Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン Download PDF

Info

Publication number
JP7638960B2
JP7638960B2 JP2022509034A JP2022509034A JP7638960B2 JP 7638960 B2 JP7638960 B2 JP 7638960B2 JP 2022509034 A JP2022509034 A JP 2022509034A JP 2022509034 A JP2022509034 A JP 2022509034A JP 7638960 B2 JP7638960 B2 JP 7638960B2
Authority
JP
Japan
Prior art keywords
alkyl
mmol
compound
mixture
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544946A5 (enExample
JP2022544946A (ja
Inventor
デン，ハイビン
リウ，ジンビャオ
オーヤン，クンドゥ
ワン，ツァ
シャオ，チータオ
シュン・グオリアン
ゼン，ハイチャン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022544946A publication Critical patent/JP2022544946A/ja
Publication of JP2022544946A5 publication Critical patent/JP2022544946A5/ja
Priority to JP2025024756A priority Critical patent/JP2025081505A/ja
Application granted granted Critical
Publication of JP7638960B2 publication Critical patent/JP7638960B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022509034A 2019-08-14 2020-08-12 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン Active JP7638960B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025024756A JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2019/100542 WO2021026803A1 (en) 2019-08-14 2019-08-14 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CNPCT/CN2019/100542 2019-08-14
PCT/IB2020/057602 WO2021028854A1 (en) 2019-08-14 2020-08-12 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025024756A Division JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Publications (3)

Publication Number Publication Date
JP2022544946A JP2022544946A (ja) 2022-10-24
JP2022544946A5 JP2022544946A5 (enExample) 2023-08-21
JP7638960B2 true JP7638960B2 (ja) 2025-03-04

Family

ID=72145436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509034A Active JP7638960B2 (ja) 2019-08-14 2020-08-12 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン
JP2025024756A Pending JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025024756A Pending JP2025081505A (ja) 2019-08-14 2025-02-19 Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Country Status (20)

Country Link
US (3) US11420970B1 (enExample)
EP (2) EP4559915A1 (enExample)
JP (2) JP7638960B2 (enExample)
KR (1) KR102946008B1 (enExample)
CN (1) CN114585622B (enExample)
AU (1) AU2020328919A1 (enExample)
BR (1) BR112022002520A2 (enExample)
CO (1) CO2022002804A2 (enExample)
DK (1) DK4013755T3 (enExample)
EC (1) ECSP22019360A (enExample)
ES (1) ES3023540T3 (enExample)
FI (1) FI4013755T3 (enExample)
IL (2) IL289754B2 (enExample)
MX (1) MX2022001784A (enExample)
MY (1) MY209614A (enExample)
PH (1) PH12022550343A1 (enExample)
PL (1) PL4013755T3 (enExample)
PT (1) PT4013755T (enExample)
WO (2) WO2021026803A1 (enExample)
ZA (1) ZA202200519B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081505A (ja) * 2019-08-14 2025-05-27 ノバルティス アーゲー Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2987269T3 (es) * 2019-09-20 2024-11-14 Novartis Ag Inhibidores de MLL1 y agentes anticancerígenos
KR20240158230A (ko) * 2022-01-05 2024-11-04 케이36 테라퓨틱스, 인크. 중수소-풍부 피페리디닐-메틸-퓨린 아민 및 관련 화합물 및 질환 및 병태 치료에 있어서 이것들의 용도
IL314895A (en) * 2022-02-16 2024-10-01 Duke Street Bio Ltd Pharmaceutical compound
IL316882A (en) * 2022-05-18 2025-01-01 K36 Therapeutics Inc Piperidinyl-methyl-purine amine D-tartaric acid salts, crystalline forms, and their use in the treatment of diseases and medical conditions
WO2023225150A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) * 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230026A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2023230038A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
WO2024073282A2 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
WO2024073283A1 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
WO2024129670A1 (en) * 2022-12-12 2024-06-20 K36 Therapeutics, Inc. Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20250171445A1 (en) * 2023-11-17 2025-05-29 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117720550A (zh) * 2023-12-14 2024-03-19 深圳市华先医药科技有限公司 (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025147514A1 (en) * 2024-01-02 2025-07-10 K36 Therapeutics, Inc. Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer
CN118459395A (zh) * 2024-05-10 2024-08-09 南通大学 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508373A (ja) 2009-10-22 2013-03-07 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
CN108853110A (zh) 2018-08-24 2018-11-23 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
KR101111085B1 (ko) * 2002-09-27 2012-04-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 아데닌 화합물 및 그 용도
JP2004137157A (ja) * 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2019196918A1 (zh) 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
KR20240158230A (ko) 2022-01-05 2024-11-04 케이36 테라퓨틱스, 인크. 중수소-풍부 피페리디닐-메틸-퓨린 아민 및 관련 화합물 및 질환 및 병태 치료에 있어서 이것들의 용도
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
IL316882A (en) 2022-05-18 2025-01-01 K36 Therapeutics Inc Piperidinyl-methyl-purine amine D-tartaric acid salts, crystalline forms, and their use in the treatment of diseases and medical conditions
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508373A (ja) 2009-10-22 2013-03-07 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
CN108853110A (zh) 2018-08-24 2018-11-23 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081505A (ja) * 2019-08-14 2025-05-27 ノバルティス アーゲー Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン

Also Published As

Publication number Publication date
JP2025081505A (ja) 2025-05-27
CN114585622A (zh) 2022-06-03
IL289754B2 (en) 2025-09-01
CA3144542A1 (en) 2021-02-18
MX2022001784A (es) 2022-04-18
EP4013755B1 (en) 2025-01-08
EP4559915A1 (en) 2025-05-28
KR102946008B1 (ko) 2026-04-01
WO2021028854A1 (en) 2021-02-18
MY209614A (en) 2025-07-24
ZA202200519B (en) 2024-08-28
PL4013755T3 (pl) 2025-05-12
US11420970B1 (en) 2022-08-23
DK4013755T3 (da) 2025-03-31
PT4013755T (pt) 2025-05-02
CN114585622B (zh) 2024-08-09
ES3023540T3 (en) 2025-06-02
US20230002388A1 (en) 2023-01-05
IL289754B1 (en) 2025-05-01
IL320143A (en) 2025-06-01
IL289754A (en) 2022-03-01
CO2022002804A2 (es) 2022-04-08
EP4013755A1 (en) 2022-06-22
BR112022002520A2 (pt) 2022-05-10
PH12022550343A1 (en) 2023-03-13
ECSP22019360A (es) 2022-04-29
US12312353B2 (en) 2025-05-27
US20250276971A1 (en) 2025-09-04
JP2022544946A (ja) 2022-10-24
FI4013755T3 (fi) 2025-04-02
WO2021026803A1 (en) 2021-02-18
KR20220047330A (ko) 2022-04-15
AU2020328919A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
ES3023540T3 (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
JP6242885B2 (ja) ５−アザインダゾール化合物及び使用方法
CN101573361B (zh) 作为plk1抑制剂的氨基嘧啶衍生物
JP2025515285A (ja) 大環状複素環及びその使用
WO2024044570A1 (en) Compounds and methods for modulating her2
KR102779693B1 (ko) Mll1 억제제 및 항암제
JP7349016B2 (ja) Ｍｌｌ１阻害剤及び抗癌剤
CA3144542C (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
HK40075573B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
HK40075573A (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
EA047083B1 (ru) Пиперидинил-метил-пуринамины в качестве ингибиторов nsd2 и противораковых средств
WO2024059559A1 (en) Isothiazolylcarboxamide compounds and their use in therapy
TW202434589A (zh) 巨環雜環及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250219

R150 Certificate of patent or registration of utility model

Ref document number: 7638960

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150